A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Ascending Dose Study of CNTO 7160 in Subjects With Asthma and Subjects With Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
At a glance
- Drugs GSK-3772847 (Primary)
- Indications Asthma; Atopic dermatitis
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 21 Apr 2017 Status changed from active, no longer recruiting to completed.
- 14 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 17 Mar 2017.